Aspen Neuroscience Pursues Autologous Cell Therapies for Parkinson’s with $147.5M Series B

The Scripps Research spinout eyes 2023 for dosing of its first patients with its first product, designed to treat idiopathic Parkinson’s disease.

MENU
Aspen Neuroscience Logo
Powered by  GDPR Cookie Compliance (opens in a new tab)
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.